A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

NCT04649151 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

4328

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: mRNA-1273
BIOLOGICAL: Placebo
BIOLOGICAL: mRNA-1273.222

Sponsor

ModernaTX, Inc.

Collaborators

[object Object]